Background Galectins are a family of proteins that have recently emerged as regulators of cancer biology. Objectives To investigate the impact of peritumoral and tumoral galectin expression on ovarian cancer prognosis. Search strategy We searched Medline, Cochrane, and EMBASE databases from inception until March 22, 2020. Selection criteria All studies correlating galectins and ovarian cancer prognosis were selected. Data collection and analysis The literature search presented 11 studies, which contained 1034 patients. Meta‐analysis was performed with RevMan 5.3 software. Main results Studies were stratified into two groups depending on the location of galectin expression (peritumoral stroma or nucleus/cytoplasm of tumor cells). Tumoral galectin‐7 and galectin‐9 expression was significantly associated with poor overall survival (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.32–3.21, P = 0.001; OR 1.71, 95% CI 1.27–2.30, P < 0.001, respectively). The total effect of high tumoral expression of galectins in overall survival and progression‐free survival was significant (OR 1.51, 95% CI 1.02–2.23, P = 0.04; OR 2.76, 95% CI 1.73–4.40, P < 0.001, respectively). Conclusions Our results suggest that galectins are implicated in ovarian cancer prognosis; however, further research is needed to ascertain their actual importance as well as their diagnostic accuracy.

No abstract

Cystic lymphangioma (CL) is a rare benign tumour that arises from the lymphatic vessels. The most common site of presentation is the posterior triangle of the neck. 90% of the lesions are diagnosed before the age of two years old and only a small number is reported in adults. In this paper, we describe the diagnostic and treatment approach of a cervical CL in an adult male.

No abstract

No abstract